Dapsone 6.5% | Hyaluronic Acid 0.5% | Niacinamide 3%

Route: Topical application to acne-affected facial or body skin.

• Apply a thin layer to affected areas once or twice daily as directed by the prescriber.
• Gently rub in until absorbed; do not apply to eyes, lips, or mucous membranes.
• At this concentration (6.5%), dapsone gel is typically applied once daily per prescriber protocol.
• For topical use only; not for oral or ophthalmic use.

Prescriber-determined based on acne severity and patient response. Comparative context:

• FDA-approved dapsone gel is available at 5% (twice daily) and 7.5% (once daily); this compounded 6.5% concentration reflects prescriber customization between these strengths.
• Apply once daily (evening preferred) to minimize photosensitivity interactions with concurrent agents.
• Duration and frequency are individualized; typical acne treatment courses run 8–12 weeks before formal efficacy assessment.

• Dapsone (6.5%): Bacteriostatic sulfone that competitively antagonizes para-aminobenzoic acid (PABA) in bacterial folic acid synthesis (dihydropteroate synthase inhibition), though the topical acne mechanism is not fully elucidated. Anti-inflammatory activity dominates in acne: inhibits myeloperoxidase-peroxide-halide-mediated neutrophil cytotoxicity; suppresses LTB4-mediated neutrophil chemotaxis; may reduce neutrophil adhesion to IgA deposits in follicular walls.
• Hyaluronic Acid (0.5%): Endogenous glycosaminoglycan with exceptional water-binding capacity (up to 1,000× its molecular weight in water). Topically, it forms a hydrophilic film on the skin surface and penetrates superficial epidermal layers to restore moisture gradient in the stratum corneum. Reduces transepidermal water loss (TEWL) and helps mitigate the drying effects of dapsone and other acne agents.
• Niacinamide: Amide form of vitamin B3 that inhibits PARP-1 and NF-κB signaling in keratinocytes, reducing transcription of IL-1α, IL-6, TNF-α, and CXCL8; stimulates ceramide, free fatty acid, and cholesterol synthesis to restore stratum corneum barrier; inhibits sebocyte activity; reduces melanosome transfer from melanocytes to keratinocytes (lightening post-inflammatory pigmentation).

This formulation targets mild to moderate inflammatory acne, with the hyaluronic acid and niacinamide additions designed to improve tolerability and barrier support—addressing a common reason for dapsone topical therapy discontinuation. The triple combination may be particularly useful for patients with sensitive skin, rosacea-prone skin, or those prone to post-inflammatory hyperpigmentation.

Prescriber monitoring:

• Screen for G6PD deficiency before initiating dapsone, particularly in patients of African, Mediterranean, or Southeast Asian descent; while methemoglobinemia risk is low for topical dapsone, caution applies.
• Avoid concurrent oral dapsone or antimalarial medications due to additive hemolytic reaction risk.
• Monitor for methemoglobinemia symptoms (cyanosis, fatigue, headache) if used with oxidizing agents.
• Reassess at 8–12 weeks; dapsone monotherapy has modest efficacy—consider combination with retinoid or benzoyl peroxide as directed by prescriber.

Contraindications:

• G6PD deficiency or methemoglobinemia (topical dapsone relative contraindication)
• Hypersensitivity to dapsone or sulfonamides
• Current use of oral dapsone or antimalarial medications (hemolytic reaction risk)

Warnings & Precautions:

• Methemoglobinemia risk: use caution with concurrent oxidizing agents (trimethoprim-sulfamethoxazole, nitrates, benzocaine).
• Topical benzoyl peroxide applied to the same area may cause temporary yellow/orange discoloration of skin and facial hair—cosmetically reversible but advise patients.
• Pregnancy: oral dapsone is Category C; topical use during pregnancy should be evaluated individually by the prescriber.

Drug Interactions:

• Trimethoprim-sulfamethoxazole (TMP-SMX): increases systemic dapsone and metabolite levels even with topical application; avoid concurrent use.
• Benzoyl peroxide: causes temporary orange/yellow skin discoloration; apply at different times of day.
• Oral antimalarials: increased hemolytic risk; avoid combination.

Common Side Effects: Application site dryness, erythema, and oiliness/peeling (dapsone vehicle effects); rare methemoglobinemia; niacinamide and hyaluronic acid are generally very well-tolerated topically.

Store at controlled room temperature (20–25°C / 68–77°F). Protect from heat and light. Do not freeze. Keep tightly sealed. Use before the beyond-use date assigned by Genesis Compounding. Keep out of reach of children.

Why is hyaluronic acid included in an acne treatment?

Topical acne medications, including dapsone, can cause significant skin dryness, erythema, and peeling that often leads patients to discontinue treatment. Hyaluronic acid is a humectant that binds water in the skin and helps maintain hydration without clogging pores (it is non-comedogenic). Its inclusion in this formulation is designed to improve comfort and adherence to therapy.

What does niacinamide add to this acne formula?

Niacinamide reduces inflammatory cytokine production in the skin, supports the skin's moisture barrier, and can reduce post-inflammatory hyperpigmentation (dark spots) left behind after acne lesions resolve. It complements dapsone's anti-inflammatory activity through a different molecular pathway.

Should I avoid benzoyl peroxide while using this?

Using benzoyl peroxide on the same skin area at the same time as dapsone gel can cause temporary yellow or orange discoloration. If your prescriber recommends both, apply them at different times of day (e.g., dapsone in the morning, benzoyl peroxide at night) to avoid this cosmetic reaction.

Is this product FDA-approved?

Topical dapsone gel is FDA-approved at 5% (twice daily) and 7.5% (once daily) concentrations for acne vulgaris. This compounded 6.5% preparation with hyaluronic acid and niacinamide is a 503A compounded product from Genesis Compounding for a specific patient and is not FDA-approved at these exact concentrations and combination.

Who should not use dapsone topically?

Patients with G6PD deficiency or active methemoglobinemia should use topical dapsone with caution. Also avoid if you are currently taking oral dapsone or antimalarial medications, as these combinations increase the risk of hemolytic reactions. Inform your prescriber of all current medications before starting.